[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-43191-en":3,"doc-seo-43191-105":29,"detail-sidebar-cat-0-en-105":91},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":20,"is_deleted":4,"is_public":21,"is_downloadable":21,"audit_status":21,"page_count":11,"language":22,"language_code":23,"site_id":24,"html_lang":23,"table_of_contents":25,"faqs":26,"seo_title":13,"seo_description":14,"update_tm":27,"read_time":28},43191,687197207639,"Asher","https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd",7,"Healthcare","Osteonecrosis of the jaw among cancer patients in Denmark: risk and prognosis","Osteonecrosis of the jaw (ONJ) is a serious complication associated with anti-resorptive therapy used for multiple myeloma and bone metastases. Using population-based medical registries, cancer patients with multiple myeloma or solid tumors receiving anti-resorptive treatment and/or having bone metastases were identified and followed for ONJ incidence. Death was treated as a competing risk to estimate cumulative ONJ incidence overall and by cancer site. Among 33,975 patients, 233 ONJ incidents yielded a 1.9% cumulative incidence over up to 7.5 years, with 5-year mortality reaching 91%.","Int. J. Oral Maxillofac. Surg. 2022; 51: 1424–1430  \n[https://doi.org/10.1016/j.ijom.2022.02.009](https://doi.org/10.1016/j.ijom.2022.02.009), available online at [https://www.sciencedirect.com](https://www.sciencedirect.com)  \nResearch Paper Clinical Pathology  \nOsteonecrosis of the jaw among cancer patients in Denmark: risk and prognosis  \nN. R. Gadgaard, T. B. Olesen, H. M. L. Svane, U. Heide-Jørgensen, S. E. Nørholt, V. Ehrenstein: Osteonecrosis of the jaw among cancer patients in Denmark: risk and prognosis. Int. J. Oral Maxillofac. Surg. 2022; 51: 1424–1430. ã 2022 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.  \nN. R. Gadgaard1,2, T. B. Olesen3,  \nH. M. L. Svane1,2, U. HeideJørgensen1,2, S. E. Nørholt4,5,  \nV. Ehrenstein1,2  \n1Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; 2 Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; 3Resources and Innovation, The Danish Clinical Quality Program (RKKP)– National Clinical Registries, Aarhus, Denmark; 4Department of Oral and Maxillofacial Surgery, Aarhus University Hospital, Aarhus, Denmark; 5Department of Dentistry and Oral Health, Aarhus University, Aarhus, Denmark  \nAbstract. Osteonecrosis of the jaw (ONJ) is a serious complication of anti-resorptive therapy used in the treatment of multiple myeloma and cancerous bone metastases. In this study, patients with either multiple myeloma or solid tumours with a simultaneous or subsequent record of anti-resorptive treatment or bone metastases were identified using population-based medical registries. These patients were followed for the outcome of ONJ. Considering death as a competing risk, the cumulative incidence of ONJ was estimated, overall and by cancer site. Patients who developed ONJ were followed for the outcome of death overall and by several risk factors for ONJ. A total of 33,975 cancer patients fulfilling the inclusion criteria were identified; 233 incidents of ONJ and a cumulative incidence of 1.9%(95% confidence interval 1.6–2.3%) over a maximum follow-up time of 7.5 years were observed. The 5-year cumulative incidence was 1.3%(95% confidence interval 1.2– 1.6%) and varied by cancer site. There were 126 deaths among cancer patients with ONJ over a maximum follow-up time of 6.4 years, resulting in a 5-year mortality of 91%(95% confidence interval 81–97%). Mortality among patients with ONJ varied by cancer site, osteonecrosis stage, and by history of trauma to the mucosa.  \nKey words: cohort studies; denosumab; diphosphonates; epidemiology; neoplasms; osteonecrosis.  \nAccepted for publication 21 February 2022 Available online 9 March 2022  \nOsteonecrosis of the jaw (ONJ) is a serious adverse effect of anti-resorptive or antiangiogenic treatment 1. Anti-resorptive agents bisphosphonates and denosumabare used for the prevention of skeletalrelated events such as pathological fractures in patients with bone metastases from solid tumours2 and in patients with multiple myeloma3,4 . Bisphosphonatesand denosumab act via different mecha-  \nnisms: bisphosphonates inhibit mature osteoclasts at sites of bone resorption, while denosumab inhibits osteoclast development, activation, and survival5. Despite these differences, both bisphosphonates and denosumab may cause ONJ. The aetiology of ONJ is thought to be related to physiological bone remodelling, inflammation, infection, inhibition of angiogenesis, and immunity  \ndysfunction6, while the location may be due to the rapid bone turnover of the alveolar process of the jaw. The medical diagnosis of ONJ requires the presence of exposed jawbone persisting for more than 8 weeks in a patient with a history of antiresorptive or anti-angiogenic treatment, and without a history of radiation therapy to the head and neck area7. The International Statistical Classification of Diseases  \n0901-5027/01101424+07 ã 2022 International Association of Oral and Maxillofacial Surgeons. Published by El","cbCaisazWQOs1jrU","https://ap.wps.com/l/cbCaisazWQOs1jrU","pdf",636235,6,1,"English","en",105,"# Abstract\n# Key Concepts and Background\n## Definition and Diagnosis\n## Epidemiology and Registry Coding\n# Materials and Methods\n## Setting and Data Sources\n## Study Population","[{\"question\":\"What is the main clinical context studied in this paper?\",\"answer\":\"The study focuses on osteonecrosis of the jaw (ONJ) in cancer patients receiving anti-resorptive therapy, particularly for multiple myeloma and cancerous bone metastases.\"},{\"question\":\"How was ONJ incidence estimated while accounting for patient outcomes?\",\"answer\":\"Death was considered a competing risk, and cumulative incidence of ONJ was estimated overall and by cancer site.\"},{\"question\":\"What were the main incidence and mortality findings in the cohort?\",\"answer\":\"Among 33,975 cancer patients, 233 developed ONJ, with a cumulative incidence of 1.9% over up to 7.5 years. Five-year mortality among patients with ONJ was reported as 91%.\"}]",1783378362,18,{"code":4,"msg":30,"data":31},"ok",{"site_id":24,"language":23,"slug":32,"title":13,"keywords":33,"description":14,"schema_data":34,"social_meta":86,"head_meta":88,"extra_data":90,"updated_unix":27},"osteonecrosis-of-the-jaw-among-cancer-patients-in-denmark-risk-and-prognosis","",{"@graph":35,"@context":85},[36,53,68],{"@type":37,"itemListElement":38},"BreadcrumbList",[39,43,47,50],{"item":40,"name":41,"@type":42,"position":21},"https://docshare.wps.com","Home","ListItem",{"item":44,"name":45,"@type":42,"position":46},"https://docshare.wps.com/document/","Document",2,{"item":48,"name":12,"@type":42,"position":49},"https://docshare.wps.com/document/healthcare/",3,{"item":51,"name":13,"@type":42,"position":52},"https://docshare.wps.com/document/osteonecrosis-of-the-jaw-among-cancer-patients-in-denmark-risk-and-prognosis/43191/",4,{"url":51,"name":13,"@type":54,"author":55,"headline":13,"publisher":57,"fileFormat":60,"inLanguage":23,"description":14,"dateModified":61,"datePublished":62,"encodingFormat":60,"isAccessibleForFree":63,"interactionStatistic":64},"DigitalDocument",{"name":9,"@type":56},"Person",{"url":40,"name":58,"@type":59},"DocShare","Organization","application/pdf","2026-07-12","2026-07-06",true,{"@type":65,"interactionType":66,"userInteractionCount":20},"InteractionCounter",{"@type":67},"ViewAction",{"@type":69,"mainEntity":70},"FAQPage",[71,77,81],{"name":72,"@type":73,"acceptedAnswer":74},"What is the main clinical context studied in this paper?","Question",{"text":75,"@type":76},"The study focuses on osteonecrosis of the jaw (ONJ) in cancer patients receiving anti-resorptive therapy, particularly for multiple myeloma and cancerous bone metastases.","Answer",{"name":78,"@type":73,"acceptedAnswer":79},"How was ONJ incidence estimated while accounting for patient outcomes?",{"text":80,"@type":76},"Death was considered a competing risk, and cumulative incidence of ONJ was estimated overall and by cancer site.",{"name":82,"@type":73,"acceptedAnswer":83},"What were the main incidence and mortality findings in the cohort?",{"text":84,"@type":76},"Among 33,975 cancer patients, 233 developed ONJ, with a cumulative incidence of 1.9% over up to 7.5 years. Five-year mortality among patients with ONJ was reported as 91%.","https://schema.org",{"og:url":51,"og:type":87,"og:title":13,"og:site_name":58,"og:description":14},"article",{"robots":89,"canonical":51},"index,follow",{"doc_id":7,"site_id":24},{"code":4,"msg":5,"data":92},[93,97,101,105,110,114,117,122,127,130,134],{"id":21,"doc_module":4,"doc_module_name":45,"category_name":94,"show_sort_weight":95,"slug":96},"Story & Novel",90,"story-novel",{"id":46,"doc_module":4,"doc_module_name":45,"category_name":98,"show_sort_weight":99,"slug":100},"Literature",80,"literature",{"id":52,"doc_module":4,"doc_module_name":45,"category_name":102,"show_sort_weight":103,"slug":104},"Exam",70,"exam",{"id":106,"doc_module":4,"doc_module_name":45,"category_name":107,"show_sort_weight":108,"slug":109},5,"Comic",60,"comic",{"id":20,"doc_module":4,"doc_module_name":45,"category_name":111,"show_sort_weight":112,"slug":113},"Technology",50,"technology",{"id":11,"doc_module":4,"doc_module_name":45,"category_name":12,"show_sort_weight":115,"slug":116},40,"healthcare",{"id":118,"doc_module":4,"doc_module_name":45,"category_name":119,"show_sort_weight":120,"slug":121},8,"Research & Report",30,"research-report",{"id":123,"doc_module":4,"doc_module_name":45,"category_name":124,"show_sort_weight":125,"slug":126},9,"Religion & Spirituality",20,"religion-spirituality",{"id":125,"doc_module":4,"doc_module_name":45,"category_name":128,"show_sort_weight":125,"slug":129},"World Cup","world-cup",{"id":131,"doc_module":4,"doc_module_name":45,"category_name":132,"show_sort_weight":131,"slug":133},10,"Lifestyle","lifestyle",{"id":135,"doc_module":4,"doc_module_name":45,"category_name":136,"show_sort_weight":106,"slug":137},19,"General","general"]